Xenetic to Acquire Santersus in All-Stock Deal, Creating NET-Targeting Leader
XBIO has more than doubled off its 52-week low of $1.9 on light trading volume (0.1× avg).
Summary
Xenetic Biosciences is acquiring privately held Santersus AG in an all-stock transaction that will transform the company into a Nasdaq-listed, multi-indication clinical-stage player focused on neutrophil extracellular traps (NETs). The combined entity, to be renamed Santersus Bio, Inc. with ticker SNTS, will have four first-in-class programs, including pivotal-stage assets in sepsis and systemic lupus erythematosus that have each received FDA Breakthrough Device Designation. Current Xenetic shareholders will own approximately 15% of the combined company, with Santersus holders owning 85%, reflecting a reverse merger structure. The deal, expected to close in Q4 2026, brings together Santersus' NucleoCapture apheresis platform and Xenetic's DNase technology, creating a dual-modality approach to NET-driven diseases across critical care, autoimmune, transplantation, and oncology. This is a transformative event for a micro-cap company with a market cap around $10 million, as it gains a much larger clinical pipeline and a new management team led by Santersus CEO James Ladtkow. The transaction requires Xenetic stockholder approval and is subject to customary closing conditions, including Nasdaq listing approval and SEC registration effectiveness.
At the time of this announcement, XBIO was trading at $4.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10M. The 52-week trading range was $1.90 to $13.93. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: ACCESS Newswire.